Key result
Smoking cessation did not significantly change cardiac troponin I concentrations over 12 weeks compared to continuous smoking (p = 0.7).
Why the study?
Observational studies paradoxically indicated lower cTnI concentrations in smokers than non-smokers, prompting examination of cTnI determinants and smoking cessation effects.
Does smoking cessation affect cardiac troponin I concentrations in overweight or obese smokers?
Cohort (n=122)
Does smoking cessation affect cardiac troponin I concentrations in overweight or obese smokers?
p-value: p=0.7
Smoking cessation over 12 weeks does not significantly affect cardiac troponin I concentrations in overweight or obese smokers, challenging prior observational data that suggested an association between smoking and lower cTn levels.
No short-term cTnI effect from cessation in obese smokers; challenges prior observational data and leaves open longer-term biomarker impact.
Chronic elevation of cardiac troponin I (cTnI) is associated with heart failure and cardiovascular death. Paradoxically, observational studies have indicated that current smokers have lower cTnI concentrations than non-smokers. We examined determinants of cTnI in smokers and the effect of smoking cessation on cTnI. Overweight or obese smokers received motivational support and varenicline to aid cessation and dietary advice to limit weight gain. Quitters were defined according to the Russell standard (≤5 cigarettes after the quit date) and validated with expired breath CO <10 ppm. Of the total 122 participants, 108 completed assessments at 12 weeks and 78 were classified as quitters versus 30 who continued smoking. cTnI was measured with a high-sensitivity assay with a limit of detection of 1.2 ng/L (Abbott Diagnostics), and concentrations (log-transformed) were compared between quitters and continuing smokers. cTnI concentrations were significantly higher in men than women and correlated with age, but not with number of cigarettes/day. Quitters had median baseline and 12-week levels of 1.4 ng/L (interquartile range [IQR] 1.2–2.5) and 1.4 ng/L (IQR 1.2–2.4), respectively, while nonquitters had baseline and 12-week levels of 1.5 ng/L (IQR 1.2–2.9) and 1.8 ng/L (IQR 1.3–3.4), respectively. The change in cTnI concentrations from baseline to 12 weeks did not differ between quitters and continuous smokers (p = .7). The results suggest that smoking cessation does not affect levels of cTnI, a marker of chronic subclinical myocardial injury, in contrast to prior observational data suggesting that tobacco smoking is associated with lower cTn concentrations.
No takes yet. Share an insight, caveat, or question.
Heggen et al. (2022) conducted a cohort in Overweight or obese smokers (n=122). Smoking cessation vs. Continuous smokers was evaluated on Change in cTnI concentrations from baseline to 12 weeks (p=0.7). Smoking cessation did not significantly change cardiac troponin I concentrations over 12 weeks compared to continuous smoking (p = 0.7).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: